FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2295717634> ?p ?o ?g. }

• W2295717634 endingPage "899" @default.
• W2295717634 startingPage "890" @default.
• W2295717634 abstract "Many patients with lung cancers cannot receive platinum-containing regimens owing to comorbid medical conditions. We designed the PPB (paclitaxel, pemetrexed, and bevacizumab) regimen to maintain or improve outcomes while averting the unique toxicities of platinum-based chemotherapies.We enrolled patients with untreated, advanced lung adenocarcinomas with measurable disease and no contraindications to bevacizumab. Participants received paclitaxel, 90 mg/m(2), pemetrexed, 500 mg/m(2), and bevacizumab, 10 mg/kg, every 14 days for 6 months and continued to receive pemetrexed and bevacizumab every 14 days until progression or unacceptable toxicity.Of the 44 patients treated, 50% were women; the median age was 61 years and 89% had a Karnofsky performance status of at least 80%. We genotyped 38 patients with the following results: Kirsten rat sarcoma viral oncogene homolog gene (KRAS), 16; anaplastic lymphoma receptor tyrosine kinase gene (ALK), three; B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) V600E, two; erb-b2 receptor tyrosine kinase 2 gene (HER2)/phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), one; epidermal growth factor receptor gene (EGFR) exon 20 insertion, one; and driver 15, none. A total of 23 patients achieved a PR (52%, 95% confidence interval: 37-68), including seven of 16 with KRAS-mutant tumors. The overall survival rate at 2 years was 43% with a median of 17 months (95% confidence interval: 10-29). Grade 3/4 treatment-related toxicities included elevated alanine transaminase level (16%), fatigue (16%), leukopenia (9%), anemia (7%), elevated aspartate transaminase level (7%), edema (5%), and pleural effusions (5%). Two patients died of respiratory failure without disease progression.The PPB regimen produced a high response rate in patients with lung adenocarcinomas regardless of mutational status. Survival and toxicities were comparable to those in the phase II reports testing platinum-containing doublets with bevacizumab. These results justify use of the PPB regimen in fit patients in whom three-drug regimens including bevacizumab are appropriate." @default.
• W2295717634 created "2016-06-24" @default.
• W2295717634 creator A5006261266 @default.
• W2295717634 creator A5012346270 @default.
• W2295717634 creator A5023629698 @default.
• W2295717634 creator A5029805571 @default.
• W2295717634 creator A5037496620 @default.
• W2295717634 creator A5039193759 @default.
• W2295717634 creator A5039791495 @default.
• W2295717634 creator A5049653532 @default.
• W2295717634 creator A5058825770 @default.
• W2295717634 creator A5068743826 @default.
• W2295717634 creator A5069643040 @default.
• W2295717634 creator A5072083393 @default.
• W2295717634 creator A5077597527 @default.
• W2295717634 creator A5091400921 @default.
• W2295717634 date "2016-06-01" @default.
• W2295717634 modified "2023-10-01" @default.
• W2295717634 title "Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas" @default.
• W2295717634 cites W121954882 @default.
• W2295717634 cites W1480012932 @default.
• W2295717634 cites W1496563114 @default.
• W2295717634 cites W1995002313 @default.
• W2295717634 cites W2019653033 @default.
• W2295717634 cites W2028461085 @default.
• W2295717634 cites W2029559869 @default.
• W2295717634 cites W2030504684 @default.
• W2295717634 cites W2040253672 @default.
• W2295717634 cites W2044307910 @default.
• W2295717634 cites W2061137007 @default.
• W2295717634 cites W2066643459 @default.
• W2295717634 cites W2068382224 @default.
• W2295717634 cites W2074142458 @default.
• W2295717634 cites W2098158939 @default.
• W2295717634 cites W2099072173 @default.
• W2295717634 cites W2099725888 @default.
• W2295717634 cites W2100785570 @default.
• W2295717634 cites W2103644933 @default.
• W2295717634 cites W2108912949 @default.
• W2295717634 cites W2109063316 @default.
• W2295717634 cites W2112089198 @default.
• W2295717634 cites W2122798232 @default.
• W2295717634 cites W2123250343 @default.
• W2295717634 cites W2125357549 @default.
• W2295717634 cites W2128002599 @default.
• W2295717634 cites W2134667653 @default.
• W2295717634 cites W2135140316 @default.
• W2295717634 cites W2136371443 @default.
• W2295717634 cites W2139248078 @default.
• W2295717634 cites W2139675556 @default.
• W2295717634 cites W2145835533 @default.
• W2295717634 cites W2147856469 @default.
• W2295717634 cites W2148011420 @default.
• W2295717634 cites W2148367564 @default.
• W2295717634 cites W2154948351 @default.
• W2295717634 cites W2155236705 @default.
• W2295717634 cites W2167191456 @default.
• W2295717634 cites W2168689345 @default.
• W2295717634 cites W2195040438 @default.
• W2295717634 cites W2225538867 @default.
• W2295717634 cites W2339024595 @default.
• W2295717634 cites W2466284809 @default.
• W2295717634 doi "https://doi.org/10.1016/j.jtho.2016.02.018" @default.
• W2295717634 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4877255" @default.
• W2295717634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26964771" @default.
• W2295717634 hasPublicationYear "2016" @default.
• W2295717634 type Work @default.
• W2295717634 sameAs 2295717634 @default.
• W2295717634 citedByCount "4" @default.
• W2295717634 countsByYear W22957176342020 @default.
• W2295717634 countsByYear W22957176342022 @default.
• W2295717634 countsByYear W22957176342023 @default.
• W2295717634 crossrefType "journal-article" @default.
• W2295717634 hasAuthorship W2295717634A5006261266 @default.
• W2295717634 hasAuthorship W2295717634A5012346270 @default.
• W2295717634 hasAuthorship W2295717634A5023629698 @default.
• W2295717634 hasAuthorship W2295717634A5029805571 @default.
• W2295717634 hasAuthorship W2295717634A5037496620 @default.
• W2295717634 hasAuthorship W2295717634A5039193759 @default.
• W2295717634 hasAuthorship W2295717634A5039791495 @default.
• W2295717634 hasAuthorship W2295717634A5049653532 @default.
• W2295717634 hasAuthorship W2295717634A5058825770 @default.
• W2295717634 hasAuthorship W2295717634A5068743826 @default.
• W2295717634 hasAuthorship W2295717634A5069643040 @default.
• W2295717634 hasAuthorship W2295717634A5072083393 @default.
• W2295717634 hasAuthorship W2295717634A5077597527 @default.
• W2295717634 hasAuthorship W2295717634A5091400921 @default.
• W2295717634 hasBestOaLocation W22957176341 @default.
• W2295717634 hasConcept C117643217 @default.
• W2295717634 hasConcept C121608353 @default.
• W2295717634 hasConcept C126322002 @default.
• W2295717634 hasConcept C143998085 @default.
• W2295717634 hasConcept C2776232967 @default.
• W2295717634 hasConcept C2776256026 @default.
• W2295717634 hasConcept C2776694085 @default.
• W2295717634 hasConcept C2777240266 @default.
• W2295717634 hasConcept C2777802072 @default.
• W2295717634 hasConcept C2778239845 @default.

• next